Table 2.

HNT nanocomposites for controlled and sustained anticancer drug delivery.

Anticancer Drug	Cell Type	HNT Modifications	Reference
Anthocyanins	MCF-7, HT-29	HNT-Anth	[114]
Atorvastatin	Caco-2, HT-29	HNT-ATV@HF-CEL	[115]
Camptothecin	HeLa	f-HNT/CPT and Fmoc-F/f-HNT/CPT	[116]
Camptothecin	Caco-2	CPT@COS/MHNTs and CPT@FA-COS/MHNTs	[117]
Curcumin	Caco-2	HNT-APT-PMVEMA@MF	[118]
Curcumin	HepG2, MCF-7, SV-HUC-1, EJ, CaSki, HeLa	HNT-COOH/Chitosan	[119]
Curcumin	SUM 149, MDA-MB-231, HL60, HL60R	f-Hal-1, 2, 4, 5, 6, and 7	[120]
Curcumin	MCF-7	PCL/PEO-Cur/HNT, PCL/PEO-Cur/HNT-GPTMS, and PCL/PEO-Cur/HNT-APTES	[121]
Doxorubicin	MCF-7	DOX@HNTs-g-COS	[122]
Doxorubicin	A549	DNA-wrapped HNTs	[123]
Doxorubicin	SKOV3, 293T	DOX@HNTs-S-S-β-CD-Ad-PEG-FA	[124]
Doxorubicin	MCF-7	DOX@HNTs-PEG-FA	[125]
Doxorubicin	HeLa	DOX loaded Fe3O4@HNT	[126]
Doxorubicin	MCF-7	Au-HNT-DOX@BSA-FA	[127]
Doxorubicin	MCF-7, COLO 205	HNT-liposome-coated surfaces	[128]
Doxorubicin	HeLa, MCF-7	HNTs-DOX conjugated with anti-EpCAM antibody	[129]